Cell Therapy for Type 1 Diabetes: What We Know About Vertex's Approach

Vertex Pharmaceuticals is developing a therapy that replaces insulin-producing cells, with early results showing promise for people with severe hypoglycemia. Here's what the evidence shows so far.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

Vertex is creating beta cells in the lab and infusing them into the liver, where they produce insulin and regulate blood sugar naturally
Early participants have achieved normal blood sugar levels without insulin injections
The therapy requires low-dose immunosuppressant medications to prevent the body from rejecting the new cells
The FDA has approved initial use in people with Type 1 diabetes and severe hypoglycemia, a group where the benefits may outweigh the risks of immunosuppression
This is an emerging therapy, not yet widely available, and long-term safety and durability data are still being gathered

How the Therapy Works

Vertex's approach involves creating functional beta cells—the insulin-producing cells that stop working in Type 1 diabetes—in a laboratory setting. These synthetic cells are then infused into the portal vein, which carries blood to the liver. Once there, the cells establish themselves and use the body's natural blood supply to function.

According to available information, these transplanted beta cells secrete insulin and glucagon, the two hormones that regulate blood sugar. In theory, they can respond to changing glucose levels much the way a healthy pancreas does, without requiring manual insulin dosing.

Early Results and Current Participants

Early reports indicate that participants who received this cell therapy have achieved normal blood sugar levels without needing insulin injections. However, detailed peer-reviewed data on the number of participants, duration of follow-up, and specific outcomes are not yet available from this source.

The FDA has granted initial approval for this therapy in a specific population: people with Type 1 diabetes who experience severe hypoglycemia—dangerous episodes of extremely low blood sugar. This targeted approval reflects the idea that for this high-risk group, the benefits of the therapy may justify the additional medical risks involved.

The Trade-Off: Immunosuppression

Because the transplanted cells come from outside the body, the immune system may try to reject them. To prevent this, recipients must take low-dose immunosuppressant medications for as long as the cells remain in place.

While these are described as low-dose medications, immunosuppression carries real considerations. Suppressing the immune system increases vulnerability to infections and carries other potential long-term effects. This is why the FDA's approval is narrowly focused on people with severe hypoglycemia, where the daily danger of life-threatening low blood sugar makes the trade-off more acceptable.

What Remains Unknown

This is an early-stage therapy, and critical questions remain unanswered. Long-term data on how long the transplanted cells continue to function, whether their effectiveness diminishes over time, and the full safety profile of low-dose immunosuppression in this context are still being studied.

Peer-reviewed research is essential for understanding these outcomes. Until larger, formally published studies are available, claims about cure or permanent remission should be approached carefully. This is promising research, but it is still research.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.